公开(公告)号：US20060002933A1

公开(公告)日：2006-01-05

申请号：US11221900

申请日：2005-09-09

申请人： Jeffrey Bluestone ,  Robert Zivin ,  Linda Jolliffe

发明人： Jeffrey Bluestone ,  Robert Zivin ,  Linda Jolliffe

IPC分类号： A61K39/395 ,  C07K16/28

CPC分类号： C07K16/2809 ,  A61K38/00 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00

摘要： The binding specificity of the murine OKT3 has been transferred into a human antibody framework in order to reduce its immunogenicity. “Humanized” anti-CD3 mAbs, such as gOKT3-5 and gOKT3-7, have been shown to retain, in vitro, all the properties of native OKT3, including T cell activation which has been correlated, in vivo, with the severe side-effects observed in transplant recipients after the first administration of the mAb. Disclosed are modified versions of humanized anti-CD3 mAbs that do not have the property of T cell activation. Further dislosed are methods of using such mAbs.

公开(公告)号：US20060292142A1

公开(公告)日：2006-12-28

申请号：US11509974

申请日：2006-08-25

申请人： Jeffrey Bluestone ,  Robert Zivin ,  Linda Jolliffe

发明人： Jeffrey Bluestone ,  Robert Zivin ,  Linda Jolliffe

IPC分类号： A61K39/395 ,  C07K16/28

CPC分类号： C07K16/2809 ,  A61K38/00 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00

摘要： The binding specificity of the murine OKT3 has been transferred into a human antibody framework in order to reduce its immunogenicity. “Humanized” anti-CD3 mAbs, such as gOKT3-5 and gOKT3-7, have been shown to retain, in vitro, all the properties of native OKT3, including T cell activation which has been correlated, in vivo, with the severe side-effects observed in transplant recipients after the first administration of the mAb. Disclosed are modified versions of humanized anti-CD3 mAbs that do not have the property of T cell activation. Further dislosed are methods of using such mAbs.

公开(公告)号：US20070238869A1

公开(公告)日：2007-10-11

申请号：US11591361

申请日：2006-11-01

申请人： Linda Joliffe ,  Robert Zivin ,  Virginia Pulito

发明人： Linda Joliffe ,  Robert Zivin ,  Virginia Pulito

IPC分类号： C07H21/04

CPC分类号： C07K16/36 ,  A61K38/00 ,  C07K2317/24 ,  C07K2317/76 ,  C07K2319/00

摘要： The present invention provides CDR-grated antibodies against human tissue factor that retain the high binding affinity of rodent monoclonal antibodies against tissue factor but have reduced immunogenicity. The present humanized antibodies are potent anticoagulants and are thus useful in the treatment and prophylaxis of human thrombotic disease. The invention also provides methods of making the CFR-grafted antibodies and pharmaceutical compositions for the attenuation or prevention of coagulation.

摘要翻译： 本发明提供了针对人组织因子的CDR-格化抗体，其保持啮齿动物单克隆抗体对组织因子的高结合亲和力，但具有降低的免疫原性。 目前的人源化抗体是有效的抗凝血剂，因此可用于治疗和预防人类血栓形成疾病。 本发明还提供了制备用于减少或预防凝血的CFR接枝的抗体和药物组合物的方法。

公开(公告)号：US20050244859A1

公开(公告)日：2005-11-03

申请号：US11081049

申请日：2005-03-14

申请人： Zhong Zhong ,  Glen Kelley ,  Thomas Mercolino ,  Robert Zivin ,  John Siekierka

发明人： Zhong Zhong ,  Glen Kelley ,  Thomas Mercolino ,  Robert Zivin ,  John Siekierka

IPC分类号： G01N33/50 ,  A61K38/00 ,  A61K38/21 ,  A61K45/00 ,  A61K48/00 ,  A61P43/00 ,  C07K14/47 ,  C07K16/18 ,  C07K19/00 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12P21/08 ,  C12Q1/28 ,  C12Q1/37 ,  C12Q1/42 ,  C12Q1/68 ,  G01N33/15 ,  C07H21/04 ,  C12N9/22 ,  C12P21/06

CPC分类号： C07K14/4705 ,  A61K38/00 ,  G01N2500/00

摘要： The present invention provides a whole-cell biological assay that measures changes of endogenous genes under control of an exogenously introduced transcription factor. The exogenous transcription factors of the present invention may be designed such that each is activated by specific extracellular ligands. Therefore cells containing exogenous transcription factors of the present invention provide a generic means to which many extracellular ligands may be tested without undue adaptation to the assay.

摘要翻译： 本发明提供了一种测量外源基因转录因子控制下内源基因变化的全细胞生物测定法。 本发明的外源性转录因子可以被设计成使得各自被特异性细胞外配体活化。 因此，含有本发明的外源性转录因子的细胞提供了一种通用方法，可以对其进行许多细胞外配体的测试，而不会对测定过度适应。

公开(公告)号：US20050203092A1

公开(公告)日：2005-09-15

申请号：US10987562

申请日：2004-11-12

申请人： Elfrida Benjamin ,  Frank Brown ,  Robert Zivin ,  Michael McMillan ,  Zhong Zhong ,  Allen Reitz ,  Tina Ross

发明人： Elfrida Benjamin ,  Frank Brown ,  Robert Zivin ,  Michael McMillan ,  Zhong Zhong ,  Allen Reitz ,  Tina Ross

IPC分类号： C07D239/12 ,  C07D239/42 ,  C07D239/52 ,  C07D401/12 ,  C07D405/04 ,  C07D409/04 ,  C07D495/04 ,  C07D413/02 ,  A61K31/506 ,  A61K31/5377 ,  C07D43/02

CPC分类号： C07D239/42 ,  C07D239/12 ,  C07D239/52 ,  C07D401/12 ,  C07D405/04 ,  C07D409/04 ,  C07D495/04

摘要： This invention provides novel neuroprotective 4-pyrimidineamine derivatives and neuroprotective pharmaceutical compositions comprising 4-pyrimidinamines. This invention also provides methods of using these compositions to prevent ischemic cell death, particularly neuronal cell death, and reduce the likelihood of neuronal cell death in a subject due to a traumatic event. Finally, this invention provides an apparatus for administering to a subject the instant pharmaceutical compositions.

摘要翻译： 本发明提供新颖的神经保护性4-嘧啶胺衍生物和包含4-嘧啶胺的神经保护药物组合物。 本发明还提供了使用这些组合物来预防缺血性细胞死亡，特别是神经元细胞死亡并降低由于创伤性事件导致受试者神经元细胞死亡的可能性的方法。 最后，本发明提供了一种向受试者施用本发明的药物组合物的装置。